Cancer PolicyFree Trump’s vaccine executive order draws criticism from medical community, may put cancer populations at risk August 14, 2026Vol.52 No.32By Claire Marie Porter
Cancer Policy HRSA redrafts 340B rebate pilot program after courts block the original version August 07, 2026Vol.52 No.31By Sara Willa Ernst
White House Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns July 31, 2026Vol.52 No.30By Jacquelyn Cobb
Regulatory News OMB proposal to sideline peer review sparks widespread oppositionNearly 500,000 public comments flood in—here are some highlights July 17, 2026Vol.52 No.28By Claire Marie Porter
Cancer Policy White House regulatory priorities include “aggressive” HHS agenda July 17, 2026Vol.52 No.28By Jacquelyn Cobb
Capitol Hill OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill July 10, 2026Vol.52 No.27By Paul Goldberg
Cancer Policy AACR urges OMB to retract proposed rule on federally funded research July 02, 2026Vol.52 No.26By Sara Willa Ernst
Cancer Policy OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya June 26, 2026Vol.52 No.25By Jacquelyn Cobb
Regulatory News Is psilocybin heading to a cancer clinic near you?Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research June 18, 2026Vol.52 No.24By Sara Willa Ernst
Cancer Policy Trump changes pick for Surgeon General, nominating Nicole Saphier May 08, 2026Vol.52 No.18By Claire Marie Porter
